Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate

Am J Hematol. 2012 Jan;87(1):131-2. doi: 10.1002/ajh.22162. Epub 2011 Sep 14.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Benzamides
  • Bone Marrow Cells / metabolism
  • Bone Marrow Cells / pathology
  • Female
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / metabolism
  • Imatinib Mesylate
  • Lymphocytes / metabolism
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptors, Antigen, T-Cell, alpha-beta / metabolism
  • Remission Induction
  • Treatment Outcome

Substances

  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptors, Antigen, T-Cell, alpha-beta
  • Imatinib Mesylate